Abiopharma

News list

(85% Positive) Global Blood Therapeutics, Inc. (GBT) Provides Update on Oxbryta for a real-world setting f

Full text

News bot Oct. 1, 2025, 3:22 p.m.
📋 Global Blood Therapeutics, Inc. (GBT) - Clinical Trial Update

Filing Date: 2022-05-12

Accepted: 2022-05-12 10:01:34

Event Type: Clinical Trial Update
Event Details:
Global Blood Therapeutics Inc (the company became a subdivision of the company Pfizer Inc (PFE)) (GBT) Announces Clinical Trial Update Global Blood Therapeutics Inc (the company became a subdivision of the company Pfizer Inc (PFE)) (GBT) provided an update on its clinical development programs. Clinical Development Highlights:
Drug Program: Oxbryta, outcomes
Diseases/Conditions: a real-world setting f, sickle cell disease
Clinical Stage: Phase 1, Phase 1 study
Collaboration: Global Blood Therapeutics, Inc.
💼 Business Developments:
- Partnership
- Acquisition: Not available
- Licensing: Not available
- Regulatory Approval
- Executive Changes: Not available
Structured Data:
- Company Name: Global Blood Therapeutics Inc (the company became a subdivision of the company Pfizer Inc (PFE))
- CIK: 0001629137
- Ticker Symbol: GBT
- Period End Date: 2022-05-12
- Document Type: 8-K